Company Description
Lexaria Bioscience Corp. operates as a biotechnology company.
It offers its patented drug delivery-enabling platform technology, DehydraTECH, which combines active pharmaceutical ingredients (APIs) with specific long-chain fatty acid-rich triglyceride oils and carrier compounds that improve the way they enter the bloodstream, increasing their effectiveness and allowing for lower overall dosing for improved tolerability while promoting healthier oral ingestion methods.
The company’s DehydraTECH is used with a range of active molecules, including glucagon-like peptide-1 drugs (GLP-1) and glucose -dependent insulinotropic polypeptide drugs (GIP), vitamins, pain medications, hormones, phosphodiesterase type 5 (PDE5) inhibitors, antivirals, nicotine and its analogs, and cannabinoids.
Its DehydraTECH technology is applied to various therapeutic indications, such as diabetes, weight loss, hypertension, and heart disease; is implemented in a multitude of ingestible or topically administered product formats comprising oral suspensions, tablets, capsules, foods, beverages, creams, lotions, and skin patches; and is suitable for a variety of product formats, including pharmaceuticals, nutraceuticals, over-the-counter products, and consumer packaged goods.
The company was formerly known as Lexaria Corp. and changed its name to Lexaria Bioscience Corp. in April 2016.
Lexaria Bioscience Corp. was incorporated in 2004 and is headquartered in Kelowna, Canada.
| Country | Canada |
| Founded | 2004 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 7 |
| CEO | Richard Christopher |
Contact Details
Address: 740 McCurdy Road, Suite 100 Kelowna, BC V1X 2P7 Canada | |
| Phone | 250 765 6424 |
| Website | lexariabioscience.com |
Stock Details
| Ticker Symbol | LEXX |
| Exchange | NASDAQ |
| Fiscal Year | September - August |
| Reporting Currency | USD |
| CIK Code | 0001348362 |
| CUSIP Number | 52886N406 |
| ISIN Number | US52886N4060 |
| Employer ID | 20-2000871 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Michael Shankman CPA | Chief Financial Officer |
| Kristin Hamilton | Director of Operations |
| Vanessa Carle | Head of Legal |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Dec 18, 2024 | 8-K | Current Report |
| Dec 17, 2024 | EFFECT | Notice of Effectiveness |
| Dec 16, 2024 | POS AM | Post-Effective amendments for registration statement |
| Dec 5, 2024 | EFFECT | Notice of Effectiveness |
| Dec 5, 2024 | 424B3 | Prospectus |
| Nov 27, 2024 | DEF 14A | Other definitive proxy statements |
| Nov 26, 2024 | S-3 | Registration statement under Securities Act of 1933 |
| Nov 26, 2024 | 10-K | Annual Report |
| Nov 14, 2024 | SC 13G/A | [Amend] Statement of acquisition of beneficial ownership by individuals |
| Nov 12, 2024 | PRE 14A | Other preliminary proxy statements |